Reversion of structure-activity relationships of antitumor platinum complexes by acetoxime but not hydroxylamine ligands

Molecular Pharmacology

Volumn 71, Issue 1, 2007, Pages 357-365

  Zorbas Seifried, Stefanie ^a   Jakupec, Michael A ^b   Kukushkin, Nikolay V ^c   Groessl, Michael ^b   Hartinger, Christian G ^b   Semenova, Olga ^b   Zorbas, Haralabos ^a   Kukushkin, Vadim Yu ^c   Keppler, Bernhard K ^b  

^a MAX PLANCK INSTITUTE OF BIOCHEMISTRY   (Germany)

^b UNIVERSITY OF VIENNA   (Austria)

^c ST PETERSBURG STATE UNIVERSITY   (Russian Federation)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DICHLOROBIS(ACETOXIME)PLATINUM; DICHLOROBIS(HYDROXYLAMINE)PLATINUM; DNA; DOUBLE STRANDED DNA; GUANOSINE PHOSPHATE; PLATINUM COMPLEX; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CAPILLARY ELECTROPHORESIS; CARCINOMA CELL; COLON CARCINOMA; COMPLEX FORMATION; CONTROLLED STUDY; CROSS LINKING; CYTOTOXICITY; DRUG DNA BINDING; DRUG DNA INTERACTION; DRUG MECHANISM; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; DEOXYGUANINE NUCLEOTIDES; HYDROXYLAMINE; KINETICS; LIGANDS; OXIMES; PLATINUM COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33845884312     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.030726     Document Type: Article

References (39)

1. Aloyz R, Xu ZY, Bello V, Bergeron J, Han FY, Yan Y, Malapetsa A, Alaoui-Jamali MA, Duncan AM, and Panasci L (2002) Regulation of cisplatin resistance and homologous recombinational repair by the TFIIH subunit XPD. Cancer Res 62:5457-5462.
2. Bellon SF, Coleman JH, and Lippard SJ (1991) DNA unwinding produced by sitespecific intrastrand cross-links of the antitumor drug cis- diamminedichloroplatinum(II). Biochemistry 30:8026-8035.
3. +. Biophys Chem 35:179-188.
4. Boccarelli A, Intini FP, Sasanelli R, Sivo MF, Coluccia M, and Natile G (2006) Synthesis and in vitro antitumor activity of platinum acetonimine complexes. J Med Chem 49:829-837.
5. Brabec V and Kasparkova J (2005) DNA interactions of platinum anticancer drugs. Recent advances and mechanisms of action, in Metal Compounds in Cancer Chemotherapy (Pérez JM, Fuertes MA, and Alonso C eds) pp 187-218, Research Signpost, Kerala.
6. Cleare MJ and Hoeschele JD (1973) Studies on the antitumor activity of group VIII transition metal complexes. Part I. Platinum(II) complexes. Bioinorg Chem 2:187-210.
7. Cohen GL, Bauer WR, Barton JK, and Lippard SJ (1979) Binding of cis- and trans-dichlorodiammineplatinum(II) to DNA: evidence for unwinding and shortening of the double helix. Science (Wash DC) 203:1014-1016.
8. Coluccia M, Boccarelli A, Mariggio MA, Cardellicchio N, Caputo P, Intini FP, and Natile G (1995) Platinum(II) complexes containing iminoethers: a trans platinum antitumour agent. Chem-Biol Interact 98:251-266.
9. Coluccia M, Nassi A, Boccarelli A, Giordano D, Cardellicchio N, Locker D, Leng M, Sivo M, Intini FP, and Natile G (1999) In vitro and in vivo antitumour activity and cellular pharmacological properties of new platinum-iminoether complexes with different configuration at the iminoether ligands. J Inorg Biochem 77:31-35.
10. Eastman A (1999) The mechanism of action of cisplatin: From adducts to apoptosis, in Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug (Lippert B ed) pp 111-134, Wiley-VCH, Weinheim, Germany.
11. Farrell N, Kelland LR, Roberts JD, and Van Beusichem M (1992) Activation of the trans geometry in platinum antitumor complexes: a survey of the cytotoxicity of trans complexes containing planar ligands in murine L1210 and human tumor panels and studies on their mechanism of action. Cancer Res 52:5065-5072.
12. Farrell N (1996) Current status of structure-activity relationships of platinum anticancer drugs: activation of the trans geometry, in Interactions of Metal Ions with Nucleotides, Nucleic Acids, and Their Constituents (Sigel A and Sigel H eds), Metal Ions in Biological Systems, vol 32, pp 603-639, Marcel Dekker, New York.
13. Hartinger C, Timerbaev AR, and Keppler BK (2003) Capillary electrophoresis in anti-cancer metallodrug research: advances and future challenges. Electrophoresis 24:2023-2037.
14. Huang H, Zhu L, Reid BR, Drobny GP, and Hopkins PB (1995) Solution structure of a cisplatin-induced DNA interstrand cross-link. Science (Wash DC) 270:1842-1845.
15. Intini FP, Boccarelli A, Francia VC, Pacifico C, Sivo MF, Natile G, Giordano D, De Rinaldis P, and Coluccia M (2004) Platinum complexes with imino ethers or cyclic ligands mimicking imino ethers: synthesis, in vitro antitumour activity, and DNA interaction properties. J Biol Inorg Chem 9:768-780.
16. Jakupec MA, Galanski M, and Keppler BK (2003) Tumour-inhibiting platinum complexes - state of the art and future perspectives. Rev Physiol Biochem Pharmacol 146:1-53.
17. Jamieson ER and Lippard SJ (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 99:2467-2498.
18. Kartalou M and Essigmann JM (2001) Recognition of cisplatin adducts by cellular proteins. Mutat Res 478:1-21.
19. 3)(thiazole)]. Protein recognition and nucleotide excision repair of monofunctional adducts. Biochemistry 42:792-800.
20. Kelland LR, Barnard CFJ, Evans IG, Murrer BA, Theobald BRC, Wyer SB, Goddard PM, Jones M, Valenti M, Bryant A, et al. (1995) Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes. J Med Chem 38:3016-3024.
21. Kukushkin VY, Izotova YA, and Tudela D (2004) Platinum(II) complexes of propanone oxime. Inorg Synth 34:81-85.
22. Kukushkin VY, Tudela D, and Pombeiro AJL (1996) Metal-ion assisted reactions of oximes and reactivity of oxime-containing metal complexes. Coord Chem Rev 156:333-362.
23. Lepre CA and Lippard SJ (1990) Interaction of platinum antitumor compounds with DNA, in Nucleic Acids and Molecular Biology (Eckstein F, Lilley DMJ eds) pp 9-38, Springer, Berlin.
24. Martin RB (1999) Platinum complexes: hydrolysis and binding to N(7) and N(1) of purines, in Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug (Lippert B ed) pp 183-205, Wiley-VCH, Weinheim, Germany.
25. Najajreh Y, Khazanov E, Jawbry S, Ardeli-Tzaraf Y, Pérez JM, Kasparkova J, Brabec V, and Barenholz Y, Gibson D (2006) Cationic nonsymmetric transplatinum complexes with piperidinopiperidine ligands. Preparation, characterization, in vitro cytotoxicity, in vivo toxicity, and anticancer efficacy studies. J Med Chem 49:4665-4673.
26. Natile G and Coluccia M (2004) Antitumor active trans-platinum compounds, in Metal Complexes in Tumor Diagnosis and as Anticancer Agents (Sigel A and Sigel H eds), Metal Ions in Biological Systems, vol 42, pp 209-250, M. Dekker, New York.
27. 2]. A concept for activation of the trans geometry in platinum antitumor complexes. Nucleic Acids Res 31:6450-6460.
28. Pérez JM, Fuertes MA, Alonso C, and Navarro-Ranninger C (2000) Current status of the development of trans-platinum antitumor drugs. Crit Rev Oncol Hematol 35:109-120.
29. 2(dimethylamine)(isopropylamine)]. Mol Pharmacol 63:933-944.
30. Stetsenko AI, Adamov OM, Dmitrieva ES, Prokhoda EF, Budnikova TI, and Dankovskaya NV (1989) inventors; Leningrad State Chemico-Pharmaceutical Institute, assignee. A method for preparation of cis-dichlorobis(hydroxylamine) platinum(II). Russ. Patent 1561488. 1989 Jan 09.
31. Takahara PM, Rosenzweig AC, Frederick CA, and Lippard SJ (1995) Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature (Lond) 377:649-652.
32. Timerbaev AR, Hartinger CG, Aleksenko SS, and Keppler BK (2006) Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology. Chem Rev 106:2224-2248.
33. Uhlenhut R (1900) Ueber Platinverbindungen mit Hydroxylamin. Liebigs Ann Chem 311:120-126.
34. Wong E and Giandomenico CM (1999) Current status of platinum-based antitumor drugs. Chem Rev 99:2451-2466.
35. 3)(quinoline)]. Eur J Biochem 254:547-557.
36. 2]. Mol Pharmacol 52:354-361.
37. Zdraveski ZZ, Mello JA, Marinus MG, and Essigmann JM (2000) Multiple pathways of recombination define cellular responses to cisplatin. Chem Biol 7:39-50.
38. Zenker A, Galanski M, Bereuter T, Keppler BK, and Lindner W (2000) Timedependent interactions of platinum(II) complexes with 5′-GMP under simulated physiological conditions studied by capillary electrophoresis. J Biol Inorg Chem 5:498-504.
39. Zorbas H and Keppler BK (2005) Cisplatin damage: are DNA repair proteins saviors or traitors to the cell? ChemBioChem 6:1157-1166.